BRISBANE, CA and ST. LOUIS, MO, May 22, 2019 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced the appointment of Kirk Christoffersen as Chief Business Officer. In this newly-created position, Mr. Christoffersen will lead Arch Oncology’s corporate strategy and other business functions reporting to Julie Cherrington, Ph.D., President and Chief Executive Officer of Arch Oncology.
“Kirk has an exceptionally strong background in business and corporate development, strategic planning, and operations which will be valuable as we further advance our pipeline of novel antibody therapies,” said Julie M. Cherrington, Ph.D., President and Chief Executive Officer of Arch Oncology. “His leadership experience and track record will help drive opportunities to create value at Arch Oncology. We welcome Kirk to the team and look forward to his contributions as we develop our pipeline of therapies to help patients with cancer.”
Kirk Christoffersen added, “It is an exciting time to join Arch Oncology as there is significant momentum across the business. There is a growing body of data on AO-176 and the pipeline, an advancing Phase 1 clinical trial for AO-176, and recent backing from leading investors in a successful Series B financing round. Julie has assembled a great team and I am eager to get to work to help unlock additional value creation opportunities for Arch Oncology and the patients we aim to serve.”
Kirk Christoffersen has over 20 years of experience in the biopharmaceutical industry. Before joining Arch Oncology, he was Senior Vice President, Corporate and Business Development for Compugen. Previously, he worked at GlobeImmune, Inc. for over a decade in roles of increasing responsibility becoming Vice President, Corporate Development. Earlier in his career, Mr. Christoffersen held leadership positions in corporate development and marketing at OSI Pharmaceuticals, Gilead Sciences, and NeXstar Pharmaceuticals. Mr. Christoffersen earned an undergraduate degree from the University of Michigan and an M.B.A. from the Daniels College of Business at the University of Denver.
About Arch Oncology
Arch Oncology, Inc. is a privately-held, clinical-stage immuno-oncology company focused on the discovery and development of best-in-class antibody therapies for the treatment of patients with cancer. The Company’s next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class. Arch Oncology’s lead product candidate AO-176 is in a Phase 1 clinical trial for the treatment of patients with select solid tumors. In addition, the Company is advancing a number of pipeline programs, including anti-signal regulatory protein (SIRP) antibodies. Arch Oncology’s leadership team has successfully developed new drugs for patients before and is backed by leading investors, including RiverVest Venture Partners, Roche Venture Fund, 3×5 RiverVest Partners II-B, and Lightchain. For more information please visit www.archoncology.com.
For Arch Oncology